AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,745,792 | +21.2% | 2,505,848 | +11.9% | 0.01% | +40.0% |
| Q2 2023 | $104,596,385 | +22.5% | 2,240,231 | +0.4% | 0.01% | 0.0% |
| Q1 2023 | $85,350,676 | -68.9% | 2,230,807 | -55.4% | 0.01% | -37.5% |
| Q4 2022 | $274,106,202 | +1370.0% | 5,001,938 | +813.4% | 0.01% | +700.0% |
| Q3 2022 | $18,647,000 | +300.4% | 547,622 | +11.1% | 0.00% | – |
| Q2 2022 | $4,657,000 | -73.5% | 492,852 | -60.2% | 0.00% | -100.0% |
| Q1 2022 | $17,583,000 | -19.5% | 1,239,117 | +20.0% | 0.00% | 0.0% |
| Q4 2021 | $21,840,000 | -15.3% | 1,032,621 | -10.5% | 0.00% | 0.0% |
| Q3 2021 | $25,794,000 | -15.4% | 1,154,101 | -6.1% | 0.00% | -50.0% |
| Q2 2021 | $30,495,000 | +11.8% | 1,229,140 | +30.8% | 0.00% | 0.0% |
| Q1 2021 | $27,271,000 | +27.7% | 940,046 | +13.5% | 0.00% | +100.0% |
| Q4 2020 | $21,359,000 | +218.8% | 827,884 | +280.4% | 0.00% | – |
| Q3 2020 | $6,700,000 | +43.3% | 217,613 | +16.0% | 0.00% | – |
| Q2 2020 | $4,675,000 | +85.7% | 187,590 | +57.9% | 0.00% | – |
| Q1 2020 | $2,518,000 | +28.9% | 118,784 | +35.0% | 0.00% | – |
| Q4 2019 | $1,953,000 | +23.6% | 88,014 | +26.7% | 0.00% | – |
| Q3 2019 | $1,580,000 | – | 69,454 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |